Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions
- 1 March 2006
- journal article
- Published by Wiley in HIV Medicine
- Vol. 7 (2) , 122-128
- https://doi.org/10.1111/j.1468-1293.2006.00356.x
Abstract
To determine the characteristics of the binding of nelfinavir and active M8 to alpha1-acid glycoprotein (AAG) and human serum albumin (HSA), and to examine the displacement effects of drugs binding extensively to AAG (ritonavir and saquinavir) or to HSA (salicylic acid and valproic acid). Free drugs were separated by equilibrium dialysis after incubation with human plasma or purified plasma proteins and after co-incubation with potential displacers. Association constants were estimated from double-reciprocal plots of the data. Nelfinavir and M8 free fractions [fractions of unbound drug (fus)] were 0.42+/-0.08% (mean+/-standard deviation) and 0.64+/-0.07%, respectively. For the two analytes, respectively, association constants were 7.25 x 10(7)/m and 3.33 x 10(7)/m for AAG and 1.11 x 10(6)/m and 7.92 x 10(5)/m for HSA. Nelfinavir fu in an AAG solution was significantly (P < 0.01) increased by the addition of ritonavir or saquinavir, whereas it was unaltered by addition of these drugs to whole plasma. Similarly, fu in an HSA solution was significantly increased (P < 0.01) by the addition of salicylic acid or valproic acid, whereas there was no difference in the free fraction in plasma. The affinity of nelfinavir for human plasma proteins was higher than that of M8, and both nelfinavir and M8 showed higher affinity to AAG than to HSA. The free fraction of nelfinavir was not affected by drugs that bind extensively to AAG or albumin when these drugs were added to whole plasma in combination, suggesting a compensatory effect of alternate binding proteins.Keywords
This publication has 17 references indexed in Scilit:
- Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral ActivitiesAntimicrobial Agents and Chemotherapy, 2001
- In Vivo Effect of α 1 -Acid Glycoprotein on Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Protease InhibitorAntimicrobial Agents and Chemotherapy, 2001
- NelfinavirDrugs, 2000
- In Vitro Effect of α1‐Acid Glycoprotein on the Anti‐Human Immunodeficiency Virus (HIV) Activity of the Protease Inhibitor CGP 61755: A Comparative Study with Other Relevant HIV Protease InhibitorsThe Journal of Infectious Diseases, 1997
- Protease Inhibitors in Patients with HIV DiseaseClinical Pharmacokinetics, 1997
- In vitro protein-binding characteristics of delavirdine and its N-dealkylated metaboliteAntiviral Research, 1996
- Measurement and Analysis of Unbound Drug ConcentrationsClinical Pharmacokinetics, 1996
- Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus TherapyThe Journal of Infectious Diseases, 1995
- Reduction Of The In Vitro Activity Of A77003, An Inhibitor Of Human Immunodeficiency Virus Protease, By Human Serum 1 Acid GlycoproteinThe Journal of Infectious Diseases, 1995
- Plasma Protein Binding and Pharmacological ResponseClinical Pharmacokinetics, 1993